Last week saw the release of a draft of the Report of the Committee on Price Negotiation for Patented Drugs. Yet, far from inspiring confidence in India's ability to get a good deal for its patients, it strikes a note of pessimism that belies the leverage that a strong generics industry and a vast and … Continue reading India’s report on patented drug pricing : on unsure ground
Apothecurry 